Top 10 Companies in the Pharmaceutical Grade Crospovidonum (PVPP) Market (2026): Market Leaders Driving Global Excipients

MARKET INSIGHTS

Global Pharmaceutical Grade Crospovidonum (PVPP) market size was valued at USD 412 million in 2024. The market is projected to grow from USD 445 million in 2025 to USD 765.21 million by 2032, exhibiting a CAGR of 7.90% during the forecast period.

Pharmaceutical Grade Crospovidonum (PVPP) is a cross‑linked polyvinylpyrrolidone polymer widely used as a superdisintegrant in solid dosage formulations. This highly effective pharmaceutical excipient enhances drug dissolution by rapidly absorbing water and swelling, which helps tablets and capsules break apart efficiently in the gastrointestinal tract. The material meets stringent pharmacopeial standards including USP, EP, and JP monographs, ensuring consistent quality for critical pharmaceutical applications.

Market growth is driven by increasing demand for fast‑acting medications, expansion of generic drug production, and technological advancements in tablet formulation. While developed markets show steady adoption, emerging economies are experiencing accelerated growth due to pharmaceutical industry expansion. However, stringent regulatory requirements and competition from alternative disintegrants pose challenges. BASF SE, Ashland Global Holdings, and JRS Pharma currently dominate the market, with these key players investing in capacity expansions to meet growing global demand.

Pharmaceutical Grade Crospovidonum (PVPP) Market – View in Detailed Research Report

Top 10 Companies in the Pharmaceutical Grade Crospovidonum (PVPP) Market (2026)

1. Ashland (USA)

Headquarters: Salem, Oregon, USA
Key Offering: Pharmaceutical grade PVPP for tablet and capsule formulations

Ashland has positioned itself as a trusted partner for global pharmaceutical manufacturers, offering PVPP that consistently meets USP, EP, and JP requirements. The company’s emphasis on analytical rigor and supply‑chain transparency has made it a preferred supplier for high‑volume generics and specialty drugs.

Sustainability & Growth Initiatives: Ashland is expanding its PVPP production capacity through a new plant in the Midwest, aiming to reduce carbon intensity per ton of product. The firm is also investing in a digital platform that tracks batch quality in real time, enhancing traceability for end users.

• Midwest capacity expansion – 25% increase in output
• Real‑time quality monitoring platform
• Partnerships with key generic manufacturers in Europe and Asia
• Commitment to ISO 14001 environmental standards

2. BASF (Germany)

Headquarters: Ludwigshafen, Germany
Key Offering: High‑purity PVPP for immediate‑release tablets

BASF’s PVPP portfolio is renowned for its uniform particle size distribution and low moisture content, attributes that translate into reliable disintegration performance across a wide range of active pharmaceutical ingredients.

Sustainability & Growth Initiatives: The company is deploying advanced membrane technology to lower energy consumption during polymer cross‑linking. Additionally, BASF’s “Green Chemistry” roadmap targets a 30% reduction in solvent usage by 2030.

• Energy‑efficient cross‑linking process
• Solvent‑reduction roadmap
• Strategic alliances with EU pharmaceutical clusters
• Investment in AI‑driven formulation optimization

3. JRS Pharma (Germany)

Headquarters: Hamburg, Germany
Key Offering: Pharmaceutical grade PVPP for tablets and ODTs

JRS Pharma focuses on niche excipient solutions, providing PVPP that meets the most demanding pharmacopeial criteria. Its strong presence in the German market gives it a competitive edge in the European generic sector.

Sustainability & Growth Initiatives: The company is piloting a closed‑loop recycling system for polymer waste, aiming to achieve zero landfill discharge by 2028.

• Closed‑loop recycling pilot
• Partnerships with German generics OEMs
• ISO 9001 quality management system
• Continuous process improvement via Six Sigma

4. Jiangxi Alpha Hi‑Tech Pharmaceutical (China)

Headquarters: Nanchang, China
Key Offering: PVPP for large‑scale generic tablet production

With a production base spanning 120,000 square meters, Jiangxi Alpha Hi‑Tech has become a major supplier for the Chinese domestic market, offering PVPP that aligns with both national and international pharmacopeial standards.

Sustainability & Growth Initiatives: The firm is expanding its capacity by 40% and integrating renewable energy sources into its manufacturing footprint.

• Capacity expansion – 40% increase
• Renewable energy integration (solar & wind)
• Compliance with China Pharmacopoeia and USP
• Strategic partnerships with local generic manufacturers

5. Anhui Sunhere Pharmaceutical Excipients (China)

Headquarters: Hefei, China
Key Offering: High‑purity PVPP for tablets and capsules

Sunhere’s PVPP is known for its low residual solvent content, making it suitable for sensitive APIs that require stringent excipient quality.

Sustainability & Growth Initiatives: The company has launched a waste‑heat recovery program to reduce operational emissions.

• Waste‑heat recovery system
• ISO 14001 environmental certification
• Investment in process automation
• Collaboration with Chinese generic OEMs

6. Boai NKY Pharmaceuticals (China)

Headquarters: Shanghai, China
Key Offering: PVPP for fast‑disintegrating tablets

Boai NKY’s PVPP is engineered to deliver rapid tablet break‑down, supporting the growing demand for orally disintegrating tablets (ODTs) in the Asian market.

Sustainability & Growth Initiatives: The company is adopting a lean‑manufacturing framework to cut waste and improve yield.

• Lean‑manufacturing implementation
• Yield optimization through real‑time analytics
• ISO 9001 quality management
• Partnerships with ODT developers

7. Guangdong Yumay Chemical (China)

Headquarters: Guangzhou, China
Key Offering: Pharmaceutical grade PVPP for tablet excipients

Yumay’s PVPP is recognized for its excellent swelling capacity, enhancing drug release in both conventional tablets and ODTs.

Sustainability & Growth Initiatives: The firm is investing in water‑recycling systems to reduce freshwater consumption.

• Water‑recycling infrastructure
• Reduced water footprint by 20%
• Compliance with Chinese and USP standards
• Strategic alliances with local pharma OEMs

8. Huangshan Bonsun Pharmaceuticals (China)

Headquarters: Huangshan, China
Key Offering: PVPP for tablet and capsule formulations

Huangshan Bonsun delivers PVPP that meets both domestic and international pharmacopeial requirements, supporting the expanding generic market.

Sustainability & Growth Initiatives: The company is implementing a circular economy model, reusing polymer scrap in secondary products.

• Circular economy model for polymer scrap
• ISO 14001 environmental compliance
• Investment in secondary product lines
• Collaboration with regional generic manufacturers

9. Jiaozuo Zhongwei Special Products Pharmaceutical (China)

Headquarters: Jiaozuo, China
Key Offering: High‑purity PVPP for tablet excipients

Jiaozuo Zhongwei’s PVPP is tailored for high‑volume tablet production, offering consistent particle size distribution and low moisture content.

Sustainability & Growth Initiatives: The firm is expanding its production line to meet rising demand in Southeast Asia.

• Production line expansion for Southeast Asian markets
• ISO 9001 quality management
• Process automation to improve consistency
• Partnerships with regional generic OEMs

10. Yuking Technology (China)

Headquarters: Beijing, China
Key Offering: PVPP for tablets and ODTs

Yuking Technology focuses on innovative PVPP formulations that support both conventional and fast‑disintegrating dosage forms.

Sustainability & Growth Initiatives: The company is adopting green chemistry principles to reduce hazardous waste.

• Green chemistry initiatives to cut hazardous waste
• ISO 14001 environmental certification
• Investment in research for next‑generation excipients
• Strategic collaborations with Chinese and global OEMs

Download FREE Sample Report

Get Full Report Here

Outlook: The Future of Pharmaceutical Grade Crospovidonum (PVPP) Market

The trajectory of the PVPP market will continue to be shaped by the demand for patient‑centric dosage forms and the need for consistent, high‑quality excipients. Key drivers include the expansion of generics in emerging economies, the rise of orally disintegrating tablets, and the integration of PVPP in biopharmaceutical formulations. Manufacturers that can deliver scalable, cost‑effective PVPP while meeting stringent regulatory demands will capture the largest share of the market.

Key Trends Shaping the Market

• Growing adoption of ODTs in pediatric and geriatric populations
• Increased focus on sustainability and green chemistry in excipient production
• Strategic capacity expansions by leading players to meet rising demand in Asia‑Pacific
• Enhanced digital traceability systems ensuring compliance with global pharmacopeial standards
• Emerging competitive pressure from alternative superdisintegrants, driving continuous innovation